We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+33.86%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.46B
AUM Growth
+$1.05B
Cap. Flow
-$233M
Cap. Flow %
-3.6%
Top 10 Hldgs %
39.98%
Holding
155
New
25
Increased
25
Reduced
25
Closed
31

Top Buys

Rank Stock Value
1
ALEC icon
Alector
ALEC
+$249M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$112M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$71.9M
4
ENDP
Endo International plc
ENDP
+$58M
5
AVDR
Avedro, Inc Common Stock
AVDR
+$53M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$259M
2
BIIB icon
Biogen
BIIB
+$235M
3
AGN
Allergan plc
AGN
+$128M
4
CVS icon
CVS Health
CVS
+$52M
5
CNC icon
Centene
CNC
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.53%
2 Financials 1.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOMX
76
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$19.5M 0.3%
5,195,330
– –
SIBN icon
77
SI-BONE Inc
SIBN
$800M
$18.6M 0.29%
985,368
– –
SVA
78
DELISTED
Sinovac Biotech, Ltd
SVA
$18.4M 0.28%
2,839,500
– –
SYRE icon
79
Spyre Therapeutics
SYRE
$8.47B
$17.4M 0.27%
86,621
– –
NVO
80
Novo Nordisk
NVO
$227B
$17.3M 0.27%
660,000
– –
DXCM icon
81
DexCom
DXCM
$29B
$16.5M 0.26%
554,800
– –
VRCA icon
82
Verrica Pharmaceuticals
VRCA
$91.9M
$16M 0.25%
147,973
– –
SYBX
83
DELISTED
Synlogic
SYBX
$15.4M 0.24%
135,333
– –
TAK icon
84
Takeda Pharmaceutical
TAK
$56.6B
$15.3M 0.24%
+750,000
New +$15.1M
SPY icon
85
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$777B
$14.1M 0.22%
+50,000
New +$13.6M
NBRV
86
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$11.3M 0.18%
18,578
– –
CNST
87
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$11.3M 0.18%
835,842
– –
SYK icon
88
Stryker
SYK
$134B
$10.7M 0.17%
54,000
-76,200
-59% -$13.7M
SCPH
89
DELISTED
scPharmaceuticals
SCPH
$10.2M 0.16%
3,409,865
– –
ELDN icon
90
Eledon Pharmaceuticals
ELDN
$260M
$10.2M 0.16%
140,951
– –
MRSN
91
DELISTED
Mersana Therapeutics
MRSN
$9.95M 0.15%
+75,645
New +$9.52M
AMRN
92
Amarin Corp
AMRN
$300M
$9.71M 0.15%
23,380
+19,330
+477% +$6.97M
VRNA
93
DELISTED
Verona Pharma
VRNA
$8.13M 0.13%
1,250,396
– –
WMGI
94
CALL
DELISTED
Wright Medical Group Inc
WMGI
$7.86M 0.12%
+250,000
New +$7.59M
AMRN
95
CALL
Amarin Corp
AMRN
$300M
$7.27M 0.11%
+17,500
New +$6.31M
FOLD
96
DELISTED
Amicus Therapeutics
FOLD
$7.05M 0.11%
518,309
+195,300
+60% +$2.39M
WVE icon
97
PUT
Wave Life Sciences
WVE
$1.13B
$6.99M 0.11%
+180,000
New +$7.3M
RNAC icon
98
Cartesian Therapeutics
RNAC
$224M
$6.82M 0.11%
95,969
+43,334
+82% +$2.75M
BMRN icon
99
BioMarin Pharmaceuticals
BMRN
$12B
$6.79M 0.11%
76,500
– –
ADVM
100
DELISTED
Adverum Biotechnologies
ADVM
$6.51M 0.1%
+124,320
New +$5.03M
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2019 Portfolio in Review

As of Q1 2019, OrbiMed held 155 positions worth $6.46B, up 19% from $5.41B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed withdrew a net $233M in Q1 2019, closing 31 positions and reducing 25 holdings. Its most notable exit was Allergan plc, an estimated $128M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Alector worth $247M.

  • OrbiMed's largest Q1 2019 buy was Alector: 13,182,329 shares worth $247M.
  • OrbiMed added most to Neurocrine Biosciences in Q1 2019, an estimated $112M increase.
  • OrbiMed's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $259M.
  • OrbiMed fully exited Allergan plc in Q1 2019, selling an estimated $128M.
  • OrbiMed's ten largest holdings make up 40% of its $6.46B portfolio in Q1 2019.
  • OrbiMed opened 25 new positions and closed 31 in Q1 2019.
  • OrbiMed's portfolio value rose 19% quarter-over-quarter to $6.46B.

Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.